ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Rating) insider James Kihara sold 5,947 shares of the company’s stock in a transaction dated Wednesday, May 17th. The stock was sold at an average price of $22.50, for a total transaction of $133,807.50. Following the completion of the sale, the insider now owns 11,144 shares in the company, […]
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Rating) CFO Mark C. Schneyer sold 15,310 shares of the stock in a transaction on Wednesday, May 17th. The shares were sold at an average price of $22.50, for a total transaction of $344,475.00. Following the transaction, the chief financial officer now owns 21,905 shares in the company, valued […]
Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Rating) reached a new 52-week high during mid-day trading on Monday . The company traded as high as $22.12 and last traded at $22.06, with a volume of 375205 shares changing hands. The stock had previously closed at $21.47. Analysts Set New Price Targets ACAD has been […]
ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Rating) had its target price lifted by JMP Securities from $22.00 to $23.00 in a research report released on Tuesday morning, The Fly reports. They currently have an outperform rating on the biopharmaceutical company’s stock. ACAD has been the subject of a number of other research reports. Credit Suisse Group […]
ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Rating) had its price objective increased by Citigroup from $21.00 to $21.60 in a report released on Tuesday, The Fly reports. ACAD has been the subject of several other reports. Cantor Fitzgerald upped their target price on shares of ACADIA Pharmaceuticals from $28.00 to $33.00 and gave the company an […]